PE20190126A1 - Proteinas de union y metodos de uso de las mismas - Google Patents

Proteinas de union y metodos de uso de las mismas

Info

Publication number
PE20190126A1
PE20190126A1 PE2018001850A PE2018001850A PE20190126A1 PE 20190126 A1 PE20190126 A1 PE 20190126A1 PE 2018001850 A PE2018001850 A PE 2018001850A PE 2018001850 A PE2018001850 A PE 2018001850A PE 20190126 A1 PE20190126 A1 PE 20190126A1
Authority
PE
Peru
Prior art keywords
methods
binding proteins
protein
gfral
antibodies
Prior art date
Application number
PE2018001850A
Other languages
English (en)
Spanish (es)
Inventor
Wenyan Shen
Jie Tang
Yan Wang
Hugo Matern
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of PE20190126A1 publication Critical patent/PE20190126A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PE2018001850A 2016-03-31 2017-03-03 Proteinas de union y metodos de uso de las mismas PE20190126A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31

Publications (1)

Publication Number Publication Date
PE20190126A1 true PE20190126A1 (es) 2019-01-17

Family

ID=59966343

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001850A PE20190126A1 (es) 2016-03-31 2017-03-03 Proteinas de union y metodos de uso de las mismas

Country Status (19)

Country Link
US (4) US10174119B2 (enExample)
EP (1) EP3436068A4 (enExample)
JP (3) JP7021099B2 (enExample)
KR (2) KR102630655B1 (enExample)
CN (2) CN117986363A (enExample)
AU (3) AU2017241161B2 (enExample)
BR (1) BR112018068898A2 (enExample)
CA (1) CA3016035A1 (enExample)
CL (1) CL2018002687A1 (enExample)
CO (1) CO2018009995A2 (enExample)
IL (1) IL261666B2 (enExample)
MX (2) MX2018011503A (enExample)
MY (1) MY194669A (enExample)
NZ (1) NZ785098A (enExample)
PE (1) PE20190126A1 (enExample)
PH (1) PH12018501882A1 (enExample)
SG (1) SG11201807279QA (enExample)
TW (2) TWI897070B (enExample)
WO (1) WO2017172260A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI897070B (zh) 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
AU2017342028A1 (en) * 2016-10-12 2019-04-11 Janssen Biotech, Inc. Methods for screening for modulators of GDF15-like biological activity
AU2019317813A1 (en) * 2018-08-10 2021-02-11 Novartis Ag GFRAL extracellular domains and methods of use
EP3920955A4 (en) * 2019-02-05 2023-02-22 The Trustees of the University of Pennsylvania GDNF FAMILY RECEPTOR-A-LIKE PEPTIDE LIGANDS (GFRAL)
US20220213187A1 (en) * 2019-05-08 2022-07-07 Agilvax Inc. Compositions and methods related to xct antibodies
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
WO2021050978A1 (en) * 2019-09-11 2021-03-18 University Of Cincinnati Treatment of skin blistering diseases using antibodies
KR102708796B1 (ko) 2020-06-04 2024-09-26 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
JP7495529B2 (ja) * 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
US20240124606A1 (en) * 2021-02-22 2024-04-18 Northwestern University Anti-cd73 monoclonal antibodies
AU2022251923A1 (en) 2021-03-31 2023-11-16 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) * 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
WO2023274276A1 (zh) * 2021-06-30 2023-01-05 上海津曼特生物科技有限公司 抗gfral抗体及其应用
US20250019427A1 (en) 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia
WO2023048425A1 (ko) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
KR102864956B1 (ko) 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
US20250382359A1 (en) 2021-12-22 2025-12-18 Byomass Inc. Targeting gdf15-gfral pathway
US20250051473A1 (en) * 2022-02-03 2025-02-13 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN119095876A (zh) * 2022-03-28 2024-12-06 科赫鲁斯生物科学有限公司 抗ilt4组合物和方法
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
WO2025029768A1 (en) 2023-07-31 2025-02-06 Ngm Biopharmaceuticals, Inc. Methods of treating nausea and vomiting disorders using anti-gfral antibodies
CN117209596B (zh) * 2023-09-01 2024-11-26 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools
WO2025244462A1 (ko) * 2024-05-24 2025-11-27 한국과학기술원 Gfral을 표적으로 하는 단일클론 항체 및 이의 용도

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
WO1997018240A1 (en) 1995-11-13 1997-05-22 Carlos Ibanez Glial cell line-derived neurotrophic factor receptors
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
BR9711763A (pt) 1996-09-11 1999-08-24 Ortho Mcneil Pharm Inc Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
AU735444B2 (en) 1997-05-06 2001-07-05 Human Genome Sciences, Inc. (Enterococcus faecalis) polynucleotides and polypeptides
EP1007072A4 (en) 1997-05-22 2002-06-26 Cephalon Inc RECEPTORS NEUROTROPHER FACTORS FROM A GLIA CELL LINE
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
JP2003526322A (ja) 1998-07-23 2003-09-09 スミスクライン ビーチャム コーポレーション 分泌型システインリッチタンパク質−６（ｓｃｒｐ−６）
JP2002526775A (ja) 1998-10-01 2002-08-20 テイテイエブスキ，アレクセイ・ウラデイミロビチ ＧＤＮＦについての新規Ｒｅｔ非依存性シグナリング経路
US6905817B1 (en) 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001250182B2 (en) 2000-04-20 2006-06-08 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
WO2002020759A2 (en) 2000-09-08 2002-03-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
EP1354042A2 (en) 2000-12-29 2003-10-22 Curagen Corporation Proteins and nucleic acids encoding same
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
JP4524074B2 (ja) 2001-03-09 2010-08-11 アーナソン， バリー ジー． 低親和性Ｆｃγレセプターを標的化する重合体の免疫グロブリン融合タンパク質
CN100448891C (zh) 2001-05-11 2009-01-07 安姆根有限公司 与tall-1结合的肽和相关分子
GB0115195D0 (en) 2001-06-21 2001-08-15 Bae Systems Plc Split-pin drill jig
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
ES2616362T3 (es) 2002-03-05 2017-06-12 Genentech, Inc. Novedosos polipéptidos que tienen similitud de secuencia con GDNFR y ácidos nucleicos que los codifican
US20100285016A1 (en) 2002-03-05 2010-11-11 Genentech, Inc. PRO34128 nucleic acids
US7576185B2 (en) * 2002-03-05 2009-08-18 Genentech, Inc. PRO34128 antibodies
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP1575512A4 (en) 2002-11-08 2007-08-29 Barnes Jewish Hospital METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
CN1241941C (zh) * 2003-11-21 2006-02-15 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
US8044179B2 (en) * 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
ES2987558T3 (es) 2006-03-24 2024-11-15 Bioverativ Therapeutics Inc PC5 como enzima de procesamiento de propéptido de factor IX
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
WO2008036437A2 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
EP2052253A2 (en) 2006-07-26 2009-04-29 Pepscan Systems B.V. Immunogenic compounds and protein mimics
CN106018820B (zh) 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
CA2666672A1 (en) * 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2008133536A2 (en) 2007-04-25 2008-11-06 Akademia Medyczna Im. Piastow Slaskich We Wroclawiu New stem cell lines, their application and culture methods
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009046495A1 (en) 2007-10-09 2009-04-16 St Vincent's Hospital Sydney Limited A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
JP5272011B2 (ja) 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
JP2011509403A (ja) 2008-01-08 2011-03-24 エフ．ホフマン−ラ ロシュ アーゲー Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
BRPI0919883A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
ES2434996T3 (es) 2008-10-31 2013-12-18 St Vincent's Hospital Sydney Limited Métodos de pronóstico en enfermedad renal crónica
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
CN102369016A (zh) 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
EP2401293B1 (en) 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
PT3248610T (pt) 2009-05-05 2024-02-01 Amgen Inc Mutantes fgf21 e suas utilizações
JP2012532608A (ja) 2009-07-08 2012-12-20 アムジェン インコーポレイテッド ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
US20130323835A1 (en) 2009-07-15 2013-12-05 Zirus, Inc. Mammalian Genes Involved in Infection
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
WO2011105573A1 (ja) 2010-02-26 2011-09-01 株式会社未来創薬研究所 抗icam3抗体およびその用途
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
EP2609427B1 (en) 2010-08-26 2015-01-21 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
WO2012047427A2 (en) 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
SI2697257T1 (sl) 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
TWI687441B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
TW201402608A (zh) * 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
CA2928851A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
CN104540848B (zh) 2012-08-08 2019-05-31 罗切格利卡特公司 白介素-10融合蛋白及其用途
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
WO2014086365A1 (en) 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
DE102013100322A1 (de) 2013-01-14 2014-07-17 Claas Selbstfahrende Erntemaschinen Gmbh Schneidwerk
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US10160793B2 (en) 2013-03-15 2018-12-25 Genentech, Inc. Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
RU2015155601A (ru) 2013-06-10 2017-07-14 Мерк Шарп И Доум Корп. Нейтрализующие цитомегаловирус (цмв) антигенсвязывающие белки
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
JP7054622B2 (ja) * 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
AU2017228489A1 (en) 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
TWI897070B (zh) 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
AU2017342028A1 (en) 2016-10-12 2019-04-11 Janssen Biotech, Inc. Methods for screening for modulators of GDF15-like biological activity
EP3841121A2 (en) 2018-08-20 2021-06-30 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
JP7495529B2 (ja) 2020-06-04 2024-06-04 テグ キョンプク インスティテュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌ拮抗抗体及びその用途
AR125037A1 (es) 2021-03-08 2023-05-31 Medimmune Llc Anticuerpos dirigidos contra gdf-15
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
AU2022251923A1 (en) 2021-03-31 2023-11-16 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2023039359A1 (en) 2021-09-10 2023-03-16 Ngm Biopharmaceuticals, Inc. Methods of treating cancer and tumor-related weight loss and cachexia

Also Published As

Publication number Publication date
US20220073627A1 (en) 2022-03-10
AU2025234197A1 (en) 2025-10-16
KR20220032645A (ko) 2022-03-15
AU2017241161A1 (en) 2018-09-20
AU2017241161B2 (en) 2022-05-26
CL2018002687A1 (es) 2019-05-10
CA3016035A1 (en) 2017-10-05
US20170306031A1 (en) 2017-10-26
JP7021099B2 (ja) 2022-02-18
MX2018011503A (es) 2018-11-09
KR102630655B1 (ko) 2024-01-30
BR112018068898A2 (pt) 2019-01-22
JP2024156852A (ja) 2024-11-06
MY194669A (en) 2022-12-12
RU2018132739A3 (enExample) 2020-09-02
US20250188174A1 (en) 2025-06-12
EP3436068A4 (en) 2020-01-15
PH12018501882A1 (en) 2019-01-28
WO2017172260A1 (en) 2017-10-05
WO2017172260A8 (en) 2017-12-28
EP3436068A1 (en) 2019-02-06
KR102370762B1 (ko) 2022-03-04
IL261666A (en) 2018-10-31
US12180289B2 (en) 2024-12-31
TWI815793B (zh) 2023-09-21
RU2018132739A (ru) 2020-04-30
NZ745635A (en) 2024-03-22
IL261666B1 (en) 2024-05-01
SG11201807279QA (en) 2018-09-27
US20190092866A1 (en) 2019-03-28
US10174119B2 (en) 2019-01-08
TWI897070B (zh) 2025-09-11
CN109715206B (zh) 2023-11-07
IL261666B2 (en) 2024-09-01
JP2022088355A (ja) 2022-06-14
AU2022224794A1 (en) 2022-09-22
JP7610541B2 (ja) 2025-01-08
JP2019513018A (ja) 2019-05-23
TW201809011A (zh) 2018-03-16
CN109715206A (zh) 2019-05-03
CN117986363A (zh) 2024-05-07
US10975154B2 (en) 2021-04-13
AU2022224794B2 (en) 2025-07-03
KR20180130524A (ko) 2018-12-07
NZ785098A (en) 2025-09-26
MX2024011328A (es) 2024-11-08
TW202423985A (zh) 2024-06-16
CO2018009995A2 (es) 2018-12-14

Similar Documents

Publication Publication Date Title
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2016006709A (es) Moduladores de aplnr y usos de estos.
UY36021A (es) Proteìnas fc multimèricas
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
PE20250392A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
CL2019003557A1 (es) Anticuerpos anti-trkb.
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
DK3681911T3 (da) Bindende proteiner til den humane trombinreceptor PAR4
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение